SeqLL 

$0.003250
21
+$0.00+0% Tuesday 17:36

統計

當日最高
0.003
當日最低
0.003
52週高點
0.00325
52週低點
0.003
成交量
146,103
平均成交量
-
市值
292,380.32
本益比
-
股息殖利率
-
股息
-

即將到來

財報

13Aug預期
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
下一步
-0.2
-0.19
-0.18
-0.17
預期EPS
-0.17
實際EPS
不適用

財務

-13.63%利潤率
未盈利
2020
2021
2022
2023
2024
2025
435.88M營收
-59.43M淨利

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

投資組合

關於

SeqLL Inc. operates globally as a life science instrumentation and specialized research services firm. Its core objective is to pioneer the development of scientific assets and proprietary intellectual property across various "omics" disciplines. Central to SeqLL's offerings is its innovative True Single Molecule Sequencing (tSMS) platform. This advanced technology provides a direct single-molecule solution for both DNA and RNA sequencing by precisely detecting individual nucleic acids. It enables researchers to analyze billions of distinct molecules in a single experimental run, thereby generating highly accurate and reproducible data. The company's solutions address a range of applications, including biomarker discovery and the creation of diagnostic assays. Its clientele is diverse, encompassing academic institutions, dedicated scientific research centers, government agencies, and companies in the biotechnology and pharmaceutical sectors. SeqLL is actively involved in numerous collaborations to further its technology and explore new applications. These include a research and development partnership with the U.S. Department of Justice's Federal Bureau of Investigation (FBI) to evaluate the forensic capabilities of direct RNA sequencing using the tSMS platform. Another significant alliance is with True Bearing Diagnostics, Inc., where tSMS is being employed to analyze whole-blood RNA to identify transcripts associated with coronary artery disease. Further collaborations extend to: The Bernstein Laboratory, focusing on fundamental questions in chromatin biology and epigenetic regulation; The Ting Laboratory; The Jackson Laboratory for Genomic Medicine, where SeqLL assists in developing novel methods for single-molecule resolution chromatin interaction analysis in individual nuclei; the Weizmann Institute of Science, recognized for its development and application of innovative single-molecule technologies; and Tetracore, Inc., to whom SeqLL supplies tSMS systems and provides on-site support. Founded in 2013, SeqLL Inc. is headquartered in Billerica, Massachusetts.
Show more...
執行長
Mr. Jeffrey M. Jagid
員工
300
國家
美國
ISIN
US81734C1146

上市

0 Comments

分享你的想法

FAQ

SeqLL 今天的股價是多少?
SQLLW 目前價格為 $0.00 USD,過去 24 小時上漲了 +0%。在圖表上更密切關注 SeqLL 股價表現。
SeqLL 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 OTC Link 交易所,SeqLL 的股票以代號 SQLLW 進行交易。
SeqLL 的市值是多少?
今天 SeqLL 的市值為 292,380.32
SeqLL 下一次財報日期是什麼時候?
SeqLL 將於 August 13, 2026 公布下一次財報。
SeqLL 上一季度的財報如何?
SQLLW 上一季度的財報為每股 -0.2 USD,預估為 -0.18 USD,帶來 -11.11% 的驚喜。下一季度的預估財報為每股 不適用 USD。
SeqLL 去年的營收是多少?
SeqLL 去年的營收為 435.88MUSD。
SeqLL 去年的淨利是多少?
SQLLW 去年的淨收益為 -59.43MUSD。
SeqLL 有多少名員工?
截至 July 30, 2026,公司共有 300 名員工。
SeqLL 位於哪個產業?
SeqLL從事於Health & Wellness產業。
SeqLL 何時完成拆股?
SeqLL 上次拆股發生於 August 31, 2023,比例為 1:40。
SeqLL 的總部在哪裡?
SeqLL 的總部位於 美國 的 Englewood Cliffs。